SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen; Ajay Nirula; Barry N. Heller; Robert Gottlieb; Joseph Boscia; Jason Morris; Gregory Huhn; José Cardona; Bharat Mocherla; Valentina Stosor; Imad Shawa; Andrew C. Adams; Jacob Van Naarden; Kenneth L. Custer; Lei Shen; M. Durante; Gerard J. Oakley; Andrew E. Schade; Janelle Sabo; Dipak Patel; Paul Klekotka; Daniel Skovronsky

doi:10.1056/nejmoa2029849

Abstract

In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.).

Keywords

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakVirologyNeutralizing antibodyBetacoronavirusPandemicMedicineAntibodyImmunologyVirusOutbreakInfectious disease (medical specialty)

Affiliated Institutions

Related Publications

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

David M. Weinreich , Sumathi Sivapalasingam , Thomas Norton +30 more

In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a hig...

2020 New England Journal of Medicine 1763 citations

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Jason D. Goldman , David Chien Lye , David S.C. Hui +23 more

In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. ...

2020 New England Journal of Medicine 1419 citations

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg , Fatima Amanat , Adolfo Firpo +15 more

SARS-CoV-2 antibodies persist As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome ...

2020 Science 1241 citations

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Angélica Jayk Bernal , Monica Maria Gomes da Silva , Dany Badibanga Musungaie +19 more

Early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19. (Funded by Merck Sharp and Dohme; MOVe-OUT Clinical...

2021 New England Journal of Medicine 1826 citations

Publication Info

Year: 2020
Type: article
Volume: 384
Issue: 3
Pages: 229-237
Citations: 1412
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1412

OpenAlex

Cite This

APA Style

                            
                                
                                    Peter Chen, 
                                
                                    Ajay Nirula, 
                                
                                    Barry N. Heller
                                
                                et al.
                            
                            (2020). 
                            SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. 
                            New England Journal of Medicine
                            , 384
                            (3)
                            , 229-237.
                            https://doi.org/10.1056/nejmoa2029849
                        

Identifiers

DOI: 10.1056/nejmoa2029849